Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
administered efgartigimod was approved by the US Food and Drug Administration (FDA) in late 2021 for the treatment of patients with gMG positive for anti-AChR IgG Abs [229]
During an evaluation, providers may review: Recommendations are based on individual medical evaluation and clinical judgment
The IV method is preferred for: Rapid Absorption: Direct infusion into the bloodstream ensures quicker and more effective distribution of glutathione throughout the body
Peer review Peer review information Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work
US$ 29.52
US$ 22.61
US$ 25.96
US$ 23.37
